AB0934 IL-6 AND ALLELIC POLYMORPHISM OF ITS GENE IN JUVENILE IDIOPATHIC ARTHRITIS

Abstract

Background The development and maintenance of inflammation in juvenile idiopathic arthritis (JIA) is mediated by cytokine imbalance; interleukin 6(IL6) plays a leading role among pro-inflammatory cytokines. Its pathological synthesis has a negative impact on all organs and system. It is not excluded that its effector ability depends on genetic structures of IL6 gene. It has not been studied whether the allelic polymorphism of the IL6-174CG gene affects the effectiveness of targeted biological therapy. Objectives: to assess the IL6 dynamics level in serum of patients with ineffective JIA-treatment. Methods The level of IL6 in the serum of JIA patients 1-18y.o. was determined using ECLIA method, debut of the disease (54) and treatment failure (36: 6 oJIA, 14 pJIA, 10 enthJIA, 6 sJIA). In patients with JIA, allelic polymorphism of the IL6-174CG gene was studied by PCR-method using allele-specific primers. A correlation analysis of clinical and laboratory parameters was made. Results Among patients with ineffective treatment of JIA, the duration of the disease was 39.5±35.8 months, 62.9% were girls. 27 patients received GC ( Analysis of the results of genetic examination showed that among children with treatment failure 50% had GC-allele of the IL-6-174GC gene, 27,3% had GG allele, and 23,7% had CC allele. Conclusion Treatment of JIA leads to changes in cytokine profile. The IL6-174CG gene is associated with a high level of IL6 in the blood. The longer the duration of the disease and the time before the start of treatment with biological DMARDs, the greater the likelihood of an increase of IL-6-level in serum. In cases of even short-term enzymemia in JIA, subclinical activity with IL-6 can be suggested. In case of presence of some signs (hyperthermia, osteoporosis, anemia) in patients with antiTNF, it is advisable to determine the level of IL-6 in blood serum. Disclosure of Interests None declared